The van Galen laboratory investigates normal and malignant hematopoiesis, with a focus on acute myeloid leukemia (AML). We use innovative experimental and computational technologies to study human cells at the transcriptional, genetic and epigenetic levels. The ultimate goal is to design new therapies that can prevent the initiation or progression of leukemia.

Biosketch
Dr. van Galen received his BSc in Biology and MSc in Cancer Genomics and Developmental Biology at Utrecht University in the Netherlands. In 2009, he joined the laboratory of Dr. John Dick at the University of Toronto with co-supervision by Dr. Maarten van Lohuizen at the University of Amsterdam. He studied transcriptional regulation and stress pathways in hematopoiesis, and graduated cum laude following his defense “Molecular regulation of human hematopoietic stem cells”. In 2014, he joined the laboratory of Dr. Bradley Bernstein at the Massachusetts General Hospital and the Broad Institute of MIT and Harvard in Boston. Dr. van Galen developed technologies to uncover epigenetic, transcriptional and genetic features of acute myeloid leukemia cells. In 2019, he joined the Hematology Division of Brigham and Women’s Hospital and the Department of Medicine of Harvard Medical School to start his laboratory.